Skip to main content

AbbVie results beat expectations despite low-cost competition to blockbuster Humira

Drugmaker raises its full-year earnings outlook, boosts 2024 dividend 4.7%
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.